Latka logo
Korro Bio logo

Korro Biorevenue & market cap

Cambridge, MassachusettsFounded 2014CEO Kieron Burrows

Public company

Korro Bio is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases.

korrobio.comLinkedInUpdated Sep 28, 2026
Annual revenue
$6.4M
Dec 2025 · Stock Analysis+181% YoY
Market cap
$140M
Sep 2026

Korro Bio revenue

Korro Bio's annual revenue was $6.4M in December 2025 (Stock Analysis). That is up 181% from $2.3M a year earlier.

$0
$2M
$4M
$6M
$0
–
$2.3M
$6.4M
20142015–2320242025
ReportedFounded 2014 at $0; every reading has its own bar
All 2 revenue readings, with sources
As ofRevenueSource
Dec 2024$2.3MStock Analysis
Dec 2025$6.4MStock Analysis

Korro Bio market cap

Korro Bio is a public company. Its market capitalisation was $140M in September 2026.

Korro Bio CEO

Kieron Burrows is CEO of Korro Bio.

Korro Bio FAQ

What is Korro Bio's revenue?

Korro Bio's annual revenue was $6.4M in December 2025, according to Stock Analysis.

Is Korro Bio publicly traded?

Yes. Korro Bio is a public company, with a market capitalisation of $140M in September 2026.

Who is the CEO of Korro Bio?

Kieron Burrows is the CEO of Korro Bio.

Categories

How this page is sourced

2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.

Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun Korro Bio? Join the podcast